Tag: HMG-CoA reductase inhibitors
The safety profile of atorvastatin is comparable with that of other HMG-CoA reductase inhibitors. Atorvastatin is generally well tolerated, and adverse reactions have usually been mild and transient. As with the other HMG-CoA reductase inhibitors, the most frequent adverse events reported for ator-vastatin were constipation, flatulence, dyspepsia and abdominal pain.
Comparative data from multicentre, randomized, clinical trials demonstrate that, at a starting dose of 10 mg/day, ator-vastatin produces greater reductions in LDL-C levels (and total cholesterol levels) than those observed with the starting doses of other HMG-CoA reductase inhibitors. Higher doses of atorvastatin are more effective than equivalent doses of other HMG-CoA reductase inhibitors and […]
Other studies evaluating costs associated with atorvasta-tin treatment are underway. As discussed earlier, several long term studies are in progress evaluating outcomes in cardiovascular events (such as incidence rates of cardiac death, non-fatal MI and surgical procedures), and these studies will also include economic assessments.
Comparison of price on the basis of a cost per percentage of cholesterol (specifically LDL-C) reduction has also been evaluated in the literature as an appropriate measure for evaluating treatment for similar degrees of cholesterol (LDL-C) reduction . This measure essentially equalizes the differences in efficacy and cost, comparing direct drug costs only. Application of […]
In some patients with homozygous FH, treatment includes LDL apheresis . In severe cases, adjunctive drug therapy is often tried in attempts to further lower LDL-C levels. Clinical data with atorvastatin have shown that at high doses (up to 80 mg/day), significant reductions in LDL-C were observed in such patients, including in some patients with […]
Atherogenic dyslipidemia’ has been suggested to be a dyslipidemic syndrome characterized by specific abnormalities in the lipoprotein profile: borderline-high LDL-C levels, elevated triglyceride levels, low HDL-C levels and the presence of small, dense, LDL particles . These abnormalities often occur together and have been suggested to impart a risk of CAD at least equal to […]
Other available treatment options often are not adequate as monotherapy for patients with elevated LDL-C and triglyceride levels (ie, combined [mixed] dyslipidemia or Fredrickson type Ilb dyslipidemia) . These patients require significant reductions in triglyceride and LDL-C levels. Whereas available statins lower LDL-C levels, they are only moderately effective in reducing triglyceride levels . On […]